Abilify

Selected form

Method of action: Antipsychotic, Psychoanaleptics, Psycholeptics

Treatment option: Fits, Schizophrenia

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Abilify

Property	Description
Active ingredient	Aripiprazole (INN)
Forms	Tablet, oral solution, solution for injection
Pharmacological class	Atypical Antipsychotic (SGA)
Mechanism Type	Dopamine-Serotonin Activity Modulator (DSA)
Origin	Synthetic Compound

What Type of Medicine is Abilify?

Abilify is a prescription-only medication that falls within the class of antipsychotic agents. The active component, Aripiprazole, is an atypical antipsychotic or second-generation antipsychotic (SGA), reflecting its advanced mechanism compared to older agents. Aripiprazole is a synthetic compound, chemically derived as a quinolinone derivative, and is a single active ingredient product. Aripiprazole is clinically utilized for managing conditions related to psychosis and mood disorders. This means that the medicine's primary role is to help stabilize severe disturbances in thought and emotion.

Composition, Forms, and General Purpose

The core function of Aripiprazole is its unique role as a dopamine-serotonin activity modulator (DSA). It works in the central nervous system by stabilizing the activity of key brain chemical messengers, acting as a partial agonist at the D2 dopamine receptors. This distinctive action is a key differentiator from many traditional antipsychotics. Aripiprazole has the potential to regulate dopamine function in the brain through its partial agonist activity. The medicine is manufactured in various dosage form(s), including oral tablets and solutions, as well as forms intended for intramuscular injection, supporting flexible administration routes. The general purpose of this psychoactive drug is to help restore better equilibrium to the thought and mood processes within the brain, particularly in patients experiencing significant emotional or perceptual instability.

Regulatory References

What side effects are possible with Abilify?

Possible Side Effects and Safety Information

The official safety profile for Aripiprazole (Abilify) details adverse reactions by frequency and physiological system, based on clinical trial data and post-marketing surveillance captured by regulatory bodies such as the FDA and EMA. The classifications are used to define the medicine’s risk characteristics in a standardized, regulatory-approved manner.

Frequency-Classified Adverse Reactions

Adverse reactions are organized into System-Organ-Classes (SOC) and classified by how often they are reported:

Very Common: Reactions reported in regulatory documents include Insomnia, Headache, and Akathisia (a feeling of restlessness).
Common: Commonly reported effects include Nausea, Vomiting, Constipation, Dizziness, Somnolence, Fatigue, Tremor, and Weight Gain. These reactions primarily affect the Nervous System and Gastrointestinal Disorders SOC categories.

Serious Adverse Reactions and Regulatory Constraints

The medicine's regulatory label explicitly documents the possibility of serious adverse reactions. These include Neuroleptic Malignant Syndrome (NMS) and Tardive Dyskinesia (a movement disorder). Significant Metabolic Changes, such as hyperglycemia and dyslipidemia, are also documented safety concerns.

The official safety profile contains important population-specific constraints. Regulatory warnings state that Aripiprazole is not approved for use in older adults with dementia-related psychosis due to an increased risk of death and cerebrovascular events. Furthermore, the risk of Suicidal Thoughts and Behaviors is noted to be higher in children, adolescents, and young adults, particularly during treatment initiation or dose changes. Safety considerations also exist for patients with a known history of cardiovascular or cerebrovascular disease due to the potential for Orthostatic Hypotension.

Overdose and Emergency Response

Aripiprazole overdose is classified in regulatory documents as a medically significant event with the potential for serious outcomes. The officially documented clinical manifestations include somnolence (drowsiness), lethargy, vomiting, and tachycardia (fast heart rate). Neurological signs such as tremor and Extrapyramidal Symptoms (EPS) are also officially reported in overdose cases. Severe or life-threatening manifestations documented in regulatory labeling include coma or unconsciousness, seizures (convulsions), metabolic acidosis, and serious cardiovascular effects like QTc prolongation.

Seek immediate medical attention for any suspected overdose. The official regulatory guidance mandates that individuals must contact a certified Poison Control Center and requires immediate hospitalization for close medical supervision. Management of an overdose is primarily general symptomatic and supportive treatment, as the regulatory label explicitly states that no specific antidote is known for aripiprazole.

Supportive measures include ensuring a patent airway and considering procedures like gastric lavage or administration of activated charcoal to reduce absorption. Due to the cardiovascular risks, continuous ECG monitoring is required during observation. Overdose reports have been documented specifically involving pediatric patients.

Therapeutic Uses of Abilify

What Abilify Treats: Main Uses and Benefits

This medicine is commonly used across conditions characterized by periods of heightened symptoms and episodic or fluctuating symptom patterns, providing support that helps ease the overall symptom burden.

Supporting Stability in Psychotic and Mood Disorders

This medicine is generally used to address symptom clusters that may become intense or disruptive. It is applied across domains where additional symptomatic support is needed for core psychotic features of Schizophrenia, and is relevant for easing the distress caused by disorganized thought, hallucinations, and delusions. In mood stabilization, it is relevant for easing the symptoms of acute and managing recurrent or episodic manifestations of Bipolar I Disorder. It is also used in a supportive role alongside other therapies for managing Major Depressive Disorder. This use offers symptomatic relief that helps patients cope more steadily with difficult episodes.

Easing Behavioral Dysregulation and Irritability

The medicine is applied across domains where additional symptomatic support is needed, particularly for specific pediatric and adolescent groups. It is relevant in clinical settings marked by increased discomfort or tension and behavioral challenges, such as severe irritability and aggression associated with Autistic Disorder. Furthermore, it is used for managing the motor and vocal tics seen in Tourette's Disorder. This provides support for improved day-to-day comfort and may assist with supporting functional stability when symptoms interfere with routine activities.

Quick Fact: Relief for Acute Distress
This medicine is commonly used when symptoms intensify, relevant when supportive symptom management is appropriate for acute agitation associated with Bipolar Mania or Schizophrenia.

Eligibility and Restrictions for Use

Eligibility and Contraindications for Abilify (Aripiprazole)

Official regulatory information outlines specific rules regarding who can and cannot use Abilify, focusing on absolute restrictions and age requirements.

Contraindications and Non-Eligibility

Classification	Population/Condition
Absolute Contraindication	Patients with known hypersensitivity to aripiprazole.
Not Approved / Prohibited Use	Elderly patients with dementia-related psychosis (due to increased risk of death).

Age-Related Eligibility Rules

Abilify is not approved for all pediatric age groups; eligibility depends on the specific condition being treated, with defined minimum ages:

Condition	Minimum Approved Age (US/EU)
Irritability with Autistic Disorder	6 years and older
Bipolar I Disorder (Manic/Mixed)	10 years and older
Schizophrenia	13 to 15 years and older (depending on region)

Eligibility Restrictions

Use in pregnancy carries a documented risk of extrapyramidal and/or withdrawal symptoms in the newborn if exposure occurs during the third trimester. Use during lactation generally requires a decision to discontinue the drug or discontinue nursing. Patients under 25 using Abilify as an adjunctive treatment for Major Depressive Disorder are subject to regulatory warnings regarding the increased risk of suicidal thoughts and behaviors.

What should I know about interactions with other medicines?

Aripiprazole (Abilify) is principally metabolized by the liver enzymes CYP2D6 and CYP3A4, forming the basis for its most significant drug interactions. Concomitant use with medications that strongly influence these enzymes requires mandatory dose adjustments to maintain appropriate drug concentrations.

Interacting Product Category	Effect on Aripiprazole Exposure	Required Oral Dose Adjustment
Strong CYP2D6 Inhibitors (e.g., quinidine, fluoxetine)	Increased	Halve the usual dose
Strong CYP3A4 Inhibitors (e.g., ketoconazole, clarithromycin)	Increased	Halve the usual dose
Strong CYP3A4 Inducers (e.g., carbamazepine, rifampin)	Decreased	Double the usual dose (over 1–2 weeks)

For patients known as CYP2D6 Poor Metabolizers, regulatory documents advise administering half the usual dose. If a CYP2D6 Poor Metabolizer is also taking a strong CYP3A4 inhibitor, the dose must be reduced further to one-quarter of the usual amount. These dose changes are generally required when the interacting drug is used concomitantly.

Caution is also necessary with other medicines that act on the central nervous system (CNS) or drugs that lower blood pressure, such as antihypertensives, due to the potential for additive effects like increased sedation or orthostatic hypotension.

Mechanism of Action

Aripiprazole, the active pharmaceutical ingredient in Abilify, primarily functions by engaging three key receptors in the central nervous system. The compound acts as a dopamine D2 receptor partial agonist and a serotonin 5-HT1A receptor partial agonist. As a partial agonist, aripiprazole binds to these receptors and elicits a submaximal response, thereby modulating dopaminergic and serotonergic signaling pathways. This activity prevents excessive activation when neurotransmitter levels are high, while still promoting some activity when levels are low. Aripiprazole also demonstrates antagonism at the 5-HT2A receptor, contributing to the drug's overall receptor binding profile. The combined action across these multiple receptor systems is hypothesized to affect intracellular signal transduction, resulting in the system-level physiological consequence of altering the basal firing rate of specific neuronal populations.

Dosage and Administration Information

How Abilify is Used

The administration of aripiprazole (Abilify) follows established methods, dosages, and schedules for its utilization. The medicine is officially delivered through two primary channels: the oral route for routine use, via tablets, oral solution, and orally disintegrating tablets (ODT), and the intramuscular (IM) injection route. IM injections are reserved for the acute, short-term management of agitation associated with specific conditions.

Official Administration Guidelines

Instruction Category	Official Usage Principle
Route & Form	Oral forms are for daily use; IM injection is for acute, limited use. The long-acting injectable forms are administered IM every month or every two months.
Dosing Schedule	Oral forms are generally taken once daily. Adult maintenance doses typically range from 10 mg to 30 mg/day for Schizophrenia and Bipolar I Disorder. For adjunctive use in Major Depressive Disorder, the maximum dose is 15 mg/day.
Titration Interval	Dose adjustments, when necessary, should only be made after a minimum interval of two weeks.
Intake Condition	Oral forms can be administered with or without food.
Preparation	Orally Disintegrating Tablets (ODT) should not be cut or chewed. Immediate-release IM injections are limited to a maximum of three doses within a 24-hour period.

Procedural Context

Initiation of treatment generally involves starting with a lower dose followed by the scheduled titration. For patients transitioning to the long-acting injectable suspension, oral aripiprazole must be continued concurrently for 14 consecutive days to ensure stable medicine levels. Specific dosage reductions are stipulated for patients who are known to be poor metabolizers of the CYP2D6 enzyme or who are taking strong CYP enzyme inhibitors.

Recent Clinical Evidence

Mechanisms and Mode of Action

Aripiprazole is an atypical antipsychotic, primarily hypothesized to act as a Dopamine D2 partial agonist and a Serotonin 5- HT1A partial agonist, while also acting as a 5- HT2A antagonist. This unique profile suggests that it modulates, rather than fully blocks, these neurotransmitter systems, aiming to stabilize activity.

Clinical Efficacy Studies

Efficacy in Schizophrenia

Clinical trials, including randomized, placebo-controlled studies, have evaluated the use of aripiprazole in acutely relapsed adult patients with schizophrenia. In a 12-week study, the active compound was associated with a statistically significant numerical difference in total scores on the Positive and Negative Syndrome Scale (PANSS) when compared to placebo.

Long-term, 52-week maintenance studies examined the compound's effect on time to relapse in adult patients with schizophrenia, finding a significant difference compared to placebo.

Efficacy in Bipolar Mania

Studies involving patients experiencing acute manic or mixed episodes of Bipolar I disorder have been conducted. Research showed that aripiprazole was associated with a statistically significant mean improvement in scores on the Young Mania Rating Scale (YMRS) compared with placebo.

Patient Profile and Tolerability Data

Tolerability Profile

Aripiprazole's tolerability profile in clinical trials often compares favorably to some older or other atypical antipsychotics, with a low propensity for causing significant weight gain or alterations in cholesterol and glucose levels compared to certain agents. In studies, common adverse events included nausea, vomiting, akathisia (inner restlessness), tremor, and somnolence (sleepiness). Most events were reported as mild or moderate and tended to occur early in the course of treatment.

Warnings and Patient Groups

Clinical data includes specific safety considerations for certain populations: Aripiprazole is not approved for the treatment of psychosis related to dementia in elderly patients due to an increased risk of cerebrovascular adverse events, including fatalities, reported in clinical trials.

Key Studies & References Dose-Dependent Efficacy of Aripiprazole in Treating Patients With Schizophrenia or Schizoaffective Disorder: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

Frequently Asked Questions (FAQ)

Common questions about Abilify (FAQ)

Q: Does Abilify have a risk of suicidal thoughts or behavior?

Regulatory information indicates that all antidepressant medications, including Abilify (aripiprazole), may be associated with an increased risk of suicidal thoughts and behavior. This risk primarily involves children, adolescents, and young adults, especially when starting the medication or changing the dose. This risk is a serious consideration, and official prescribing information highlights the need for careful monitoring in patients of all ages, particularly those under 24 years old.

Q: Can Abilify cause weight gain?

Yes, regulatory documents state that weight gain is a possible side effect of Abilify (aripiprazole) in both adults and children. In some clinical studies, both adults and pediatric patients experienced weight gain. Official product information mentions that metabolic changes, including weight changes, are a known class effect for this type of medication.

Q: Can Abilify affect my blood sugar?

According to the official product information, taking Abilify (aripiprazole) can cause changes in blood glucose (sugar) levels. This includes hyperglycemia (high blood sugar), which can potentially be severe and even lead to diabetes in rare cases. Due to this potential risk, official information indicates that blood sugar monitoring may be necessary, particularly for patients with a history of diabetes or related risk factors.

Q: Does Abilify cause sleepiness or drowsiness?

Studies and official information indicate that Abilify (aripiprazole) can cause somnolence (sleepiness or drowsiness) as a common side effect. For this reason, official product labeling indicates that patients should use caution when operating machinery or driving until they understand the medication's effect on them. It is important to know your personal response to the medication.

Q: What should I do if I miss a dose of Abilify?

Official product information generally outlines that if a dose is missed, patients are advised to take it as soon as they remember on the same day. However, if it is almost time for the next scheduled dose, the missed dose is usually skipped entirely, and the regular schedule is continued. It is also stated in the regulatory documents that taking two doses at once to compensate for a missed dose should be avoided.

Q: Can Abilify affect my cholesterol levels?

Yes, official product information indicates that Abilify (aripiprazole) can lead to changes in cholesterol and triglyceride levels, which are part of a broader set of metabolic changes associated with this class of medicines. For this reason, official documentation notes that lipid (cholesterol) levels are typically monitored during the course of treatment. This is a potential risk that patients should be aware of.

Q: What is the risk of having involuntary movements (like Tardive Dyskinesia) while taking Abilify?

According to the official product information, a condition called Tardive Dyskinesia (TD), which involves involuntary and repetitive movements, is a risk with Abilify (aripiprazole) and similar antipsychotic medications. Due to this potential, the official prescribing information notes the importance of clinical monitoring for the appearance of uncontrollable body movements. This type of monitoring helps ensure safety during treatment.

How should Abilify be stored and disposed of?

How to Store and Dispose of Abilify (Aripiprazole)

Official labeling defines strict conditions for storing and discarding Abilify to maintain stability and ensure safety.

Required Storage Conditions

Abilify Tablets and Oral Solution must be stored at controlled room temperature (20 C to 25 C / 68 F to 77 F). The Oral Solution should be stored in its original container, kept tightly closed, and must be discarded six months after the first opening.

Storage Restriction	Requirement
Temperature	Do not store above 30 C (86 F) or freeze the Oral Solution.
Child Safety	Must be stored out of the sight and reach of children.

Official Disposal Instructions

Abilify should not be flushed down a toilet or sink. The preferred method for discarding expired or unused product is through an authorized drug take-back program or collection site. If a program is unavailable, follow the official procedure of mixing the medicine with an undesirable substance (e.g., dirt or coffee grounds) and placing it in a sealed container before throwing it into the household trash, in accordance with local regulations.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.